Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATARA BIOTHERAPEUTICS, INC.

(ATRA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
16.79(c) 17.3(c) 17(c) 17.47(c) 17.655 Last
893 237 670 831 391 142 827 582 94 431 Volume
+2.50% +3.04% -1.73% +2.76% +1.06% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 15,7 M - -
Net income 2021 -343 M - -
Net cash position 2021 210 M - -
P/E ratio 2021 -4,72x
Yield 2021 11,4%
Sales 2022 36,2 M - -
Net income 2022 -356 M - -
Net cash position 2022 127 M - -
P/E ratio 2022 -4,90x
Yield 2022 11,4%
Capitalization 1 481 M 1 481 M -
EV / Sales 2021 80,9x
EV / Sales 2022 37,4x
Nbr of Employees 558
Free-Float 99,4%
More Financials
Company
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The... 
More about the company
Ratings of Atara Biotherapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about ATARA BIOTHERAPEUTICS, INC.
08:11aATARA BIOTHERAPEUTICS : European Medicines Agency Grants Atara Biotherapeutics Accelerated..
AQ
09/27ATARA BIOTHERAPEUTICS : Secures Accelerated Assessment For Lead Product Candidate In EU
MT
09/27ATARA BIOTHERAPEUTICS : European Medicines Agency Grants Atara Biotherapeutics Accelerated..
BU
09/27European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Ce..
CI
09/06ATARA BIOTHERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
09/03ATARA BIOTHERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
09/02ATARA BIOTHERAPEUTICS : to Participate in a Panel Discussion at the Citi 16th Annual BioPh..
BU
08/19INSIDER TRENDS : 90-Days of Insider Buying at Atara Biotherapeutics Eased Back with Share ..
MT
08/10ATARA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/09ATARA BIOTHERAPEUTICS : Q2 Earnings Snapshot
AQ
08/09ATARA BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/09Atara Biotherapeutics Mulls Acquisitions
CI
08/09ATARA BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/09ATARA BIOTHERAPEUTICS : Announces Second Quarter 2021 Financial Results and Operational Pr..
BU
08/09ATARA BIOTHERAPEUTICS : Appoints Cell Therapy and Oncology Commercialization Veteran Ameet..
BU
More news
News in other languages on ATARA BIOTHERAPEUTICS, INC.
09/27Atara Biotherapeutics obtient une évaluation accélérée de son principal produit candida..
2020DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 07.12.2020 - 15.15 Uhr
2020ATARA BIOTHERAPEUTICS : UPDATE/Bayer steigt in CAR-T-Zelltherapien gegen Krebs ein
2020La BCE vient passer la seconde couche
2020EN DIRECT DES MARCHES : Axa, Société Générale, Europcar, Altice Europe, Mastercard, EQT, W..
More news
Analyst Recommendations on ATARA BIOTHERAPEUTICS, INC.
More recommendations
Chart ATARA BIOTHERAPEUTICS, INC.
Duration : Period :
Atara Biotherapeutics, Inc. Technical Analysis Chart | ATRA | US0465131078 | MarketScreener
Technical analysis trends ATARA BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 17,47 $
Average target price 33,38 $
Spread / Average Target 91,0%
EPS Revisions
Managers and Directors
Pascal Touchon President, Chief Executive Officer & Director
Utpal Koppikar Chief Financial Officer & Senior Vice President
Ronald C. Renaud Non-Executive Chairman
Manher AJ Joshi Chief Medical Officer
Jakob Dupont Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ATARA BIOTHERAPEUTICS, INC.-11.00%1 481
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582